Skip to content
Review Open access

860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation

Sep 2026 · International Journal of Neuropsychopharmacology · Vol 29, pp. i274 - i274 · 0 citations

TL;DR

A narrative review integrating preclinical and clinical studies investigating glutamatergic mechanisms in mood disorders, focusing on NMDA and AMPA receptor dynamics, intracellular signaling pathways (including mTORC1 and eIF4E-dependent translation), and circuit-level adaptations.

Abstract

Abstract Background While the monoaminergic hypothesis has long dominated the treatment of mood disorders, its limitations have prompted the exploration of alternative mechanisms. Early work by Skolnick et al. (1996) demonstrated that chronic antidepressant treatment induces adaptive changes in N-methyl-D-aspartate (NMDA) receptors, suggesting glutamatergic signaling as a convergent pathway in antidepressant action. This framework set the stage for a paradigm shift toward synaptic plasticity as a central mechanism in mood disorders in the last decades. Aims & Objectives The AIM is to present a narrative review integrating preclinical and clinical studies investigating glutamatergic mechanisms in mood disorders, focusing on NMDA and AMPA receptor dynamics, intracellular signaling pathways (including mTORC1 and eIF4E-dependent translation), and circuit-level adaptations. Key translational studies form literature and Gobbi’s lab involving ketamine and serotonergic hallucinogens are included. Method Literature review was conducted using Medline, Embase, CINAHL, and PsycInfo from database inception to May 2026. Searches were performed using Covance software, focusing on studies investigating glutamatergic signaling, NMDA and AMPA receptor function, neuroplasticity, and rapid-acting antidepressants. Both preclinical and clinical studies were included. Results Preclinical and clinical studies show that stress and depressive-like states are associated with impaired glutamatergic transmission, synaptic atrophy, and reduced dendritic spine density in cortico-limbic regions. Building on the NMDA receptor antagonism hypothesis (Trullas and Skolnik, 1990; Moghaddam, 1993; Skolnick et al., 1996), ketamine was shown to produce rapid antidepressant effects in treatment-resistant depression (Zarate et al., 2006). Mechanistically, ketamine induces NMDA receptor blockade, leading to glutamate surge and enhanced AMPA receptor throughput, a process required for its antidepressant effects (Krystal et al., 2013). At the molecular level, ketamine activates mTORC1 signaling and cell-specific protein synthesis via eIF4E-dependent mechanisms, promoting synaptogenesis (Aguilar-Valles et al., 2021). These effects unfold in a temporally organized manner, linking early synaptic potentiation to sustained structural plasticity. Recent converging evidence indicates that serotonergic psychedelics engage similar glutamatergic plasticity pathways. LSD promotes social behavior and synaptic plasticity via facilitation of the AMPA receptors and mTORC1 in excitatory neurons (De Gregorio et al., 2021, PNAS), and broader work highlights shared mechanisms across LSD, psilocybin, MDMA, and ketamine (De Gregorio et al., 2021, J Neurosci). Recent integrative models further emphasize circuit-level disinhibition and synaptic remodeling as core mechanisms underlying rapid-acting antidepressants (Krystal et al., 2023). Discussion & Conclusions Glutamatergic signaling has emerged as a central framework linking synaptic plasticity to the pathophysiology and treatment of mood disorders. From NMDA receptor adaptations to rapid-acting antidepressants such as ketamine and psychedelics, this paradigm shift redefines mood disorders as disorders of neuroplasticity. Future work should focus on developing safer glutamatergic modulators and biomarker-driven approaches to optimize clinical translation.

Read PDF

Similar papers

Review Open access Sep 2026

704. Targeting the Glutamatergic System: Novel Therapeutics in Unipolar and Bipolar Depression

Abstract Background Glutamatergic dysfunction is increasingly recognized as a core mechanism in both unipolar and bipolar depression, contributing to impaired neuroplasticity, disrupted excitatory–inhibitory balance, and treatment resistance. Emerging therapies that modulate glutamate pathways—particularly NMDA recepto...

A. Young · 0 citations
Open access Sep 2026

452. Primary neuronal cultures to study neuroplastic effects of hallucinogen drugs

Preliminary findings suggest that the in vitro stress protocol induces structural and synaptic alterations, and that ketamine rapidly affects expression of several proteins involved in synaptic plasticity.

N. Nicosia, J. Mingardi, G. Terribile et al. · 0 citations
Review Aug 2026

An Integrative Model of Ketamine-Induced Memory Dysfunction: From Synapse to Circuit in Clinical Context.

Ketamine presents a modern pharmacological paradox, acting as both a rapid-acting antidepressant and a drug of abuse with significant cognitive consequences. While its therapeutic potential is revolutionary, chronic exposure is increasingly associated with persistent and specific deficits in episodic and working memory...

Mola Mohammadi, Amin Saeedi, A. A. K. Vakilabad et al. · 0 citations
Review Aug 2026

Altered glutamatergic neurotransmission in the development and maintenance of PTSD.

In conclusion, altered glutamatergic neurotransmission represents a central mechanism in PTSD pathophysiology and its role in synaptic plasticity, neuronal vulnerability, and network dysregulation highlights its potential relevance as a diagnostic and therapeutic target.

E. Ogłodek · 0 citations
Sep 2026

The serotonin 1B receptor as a target for the treatment of depression and anxiety.

INTRODUCTION Depressive and anxiety disorders impose a substantial public health burden, yet current serotonergic therapies are limited by delayed onset, modest remission rates, and adverse side effects. Here we put forward the serotonin 1B receptor (5-HT1BR) as an important therapeutic target for mood related patholog...

Sixtine Fleury, Katherine M. Nautiyal · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.